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j ourna l homepage: www.e lsev ie r .com/ locate /bbamemEditorialMembrane channels and transporters in cancersCancer pathogenesis involves dynamic changes in the genome that
ultimately impair normal tissue homeostasis and drive the transforma-
tion of normal cells into malignant derivatives that exhibit uncontrolled
multiplication and spreading. Among the genes affected during malig-
nant transformation, it is inevitable that those encoding membrane
channels and transporters are included. Ion andmoleculeﬂuxes through
membranes deﬁne cell membrane potential and volume, are involved in
intracellular signaling events and activate speciﬁc cellular responses.
The present issue of Biochimica et Biophysica Acta-Biomembranes enti-
tled “ Membrane channels and transporters in cancers” summarizes the
current state of knowledge from three principal standpoints: the main
families of membrane channels involved in the pathophysiology of can-
cers, the cancers and alterations in the activities of membrane channels,
and the membrane channels in cancer management strategies.
1. Main families of membrane channels involved in the
pathophysiology of cancers
Potassium channels, the most diverse and ubiquitous class of ion
channels, control membrane potential and contribute to nerve and
cardiac action potentials and neurotransmitter release. But they are
also involved in insulin release, differentiation, activation, proliferation,
apoptosis, and several other physiological functions as well as in the
regulatory mechanisms of neoplastic cell proliferation and survival.
Several K+ channel families, such as the voltage-gated K+ channels,
the ether à-go-go K+ channels, the two pore domain K+ channels and
the Ca2+-activated K+ channels, have been associated to tumor biology.
N. Comes, A. Serrano-Albarrás, J. Capera, C. Serrano-Novillo, E. Condom,
S. Ramón Y Cajal, J.C. Ferreres and A. Felipe [1] summarize available data
on K+ channels that exhibit oncogenic properties and have been linked
to a more malignant cancer phenotype.
Voltage-gated sodium channels (VGSCs), macromolecular protein
complexes containing a pore-forming α subunit and smaller non-
pore-forming β subunits, are critically important for electrogenesis.
Both the α and β subunits also interact with a range of other signaling
molecules, enabling ﬁne-tuning of channel activity and allowing
VGSCs to participate in non-conducting signaling pathways. VGSCs
are abnormally expressed in metastatic cells from a number of cancers,
where Na+ current carried by α subunits is considered to enhance mi-
gration, invasion and metastasis in vivowhereas the β subunits would
mediate cellular adhesion and process extension. P. Besson, V. Driffort,
É. Bon, F. Gradek, S. Chevalier and S. Roger [2] examine the pathological
roles played by VGSCs during cancer progression toward metastasis.
The calcium ion serves as a ubiquitous secondmessenger in eukaryot-
ic cells and changes in the intracellular Ca2+ concentration, with spatial
localization, magnitude and temporal characteristics, regulate a plethorahttp://dx.doi.org/10.1016/j.bbamem.2015.06.017
0005-2736/© 2015 Elsevier B.V. All rights reserved.of physiological functions. Cellular Ca2+ signaling is established by
the concerted activity of several partners, including active energy-
dependent Ca2+ transporters, Ca2+ membrane channels, Ca2+-
binding and storage proteins (referred to as the “molecular toolkit” for
calcium signaling) to both maintain cellular homeostasis and carry out
speciﬁc cellular functions. Deregulation of the calcium signal is often
deleterious and can be a feature of certain pathological states, including
cancer. Teneale A. Stewart, Kunsala T.D.S. Yapa and Gregory R.Monteith
[3] explain how the important role of calcium signaling in proliferation,
cell death, and invasion and metastasis, represents multiple opportuni-
ties for targeting altered calcium signaling during the course of tumor-
igenesis. Nadine Deliot and Bruno Constantin [4] more speciﬁcally
focus on two classes of non-voltage-operated Ca2+ channels, transient
receptor potential (TRP) channels and ORAI-mediated store-operated
channels, two Ca2+ inﬂux pathways frequently altered in cancer cells.
Chloride channels comprise a functionally and structurally diverse
group of anion selective channels that in part determine cell membrane
potential, modify transepithelial transport, and maintain intracellular
pH and cell volume but also contribute in cell cycle, angiogenesis, apo-
ptosis, cell adhesion, and cellmotility. Duringneoplastic transformation,
high rate of proliferation, active migration, and invasiveness require
partial or total involvement of chloride channel activity. In this context,
this class of membrane proteins could represent valuable therapeutic
targets for the treatment of resistant tumors. M. Peretti, M. Angelini,
N. Savalli, T. Florio, S.H. Yuspa andM. Mazzanti [5] focus on the associa-
tion of chloride intracellular channels 1 and 4 (CLIC1, CLIC4) proteins
with malignant transformation and how they could represent novel
therapeutic targets.
Voltage-dependent anion channels (VDACs), a class of porin ion
channel present at the outer mitochondrial membrane, occupy a crucial
position in the cell, serving as themain interface betweenmitochondrial
and cellular metabolisms by mediating transport of ions and metabo-
lites. Accumulating evidence also points to VDAC as being a key player
in the regulation of mitochondria-mediated apoptosis and implicated
in cancer and neurodegenerative disorders. V. Shoshan-Barmatz,
D. Ben-Hail, L. Admoni, Y. Krelin and S.S. Tripathi [6] outline current
knowledge related to VDAC1 as a multi-functional mitochondrial
protein regulating cell life and death and its importance for cancer cell
survival. Speciﬁcally, they highlight recent results related to the modu-
lation of VDAC1 activities by associated proteins and suggest a novel
mechanism for VDAC1-mediated release of apoptotic proteins and reg-
ulation of apoptosis.
Aquaporins (AQPs) are a family of small, integral transmembrane
proteins that assemble as homotetramers to form a central pore able
to transportwater across cell plasmamembranes in response to osmotic
gradients. However, if some of them (for example, AQP1, AQP2, AQP4,
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(AQP3, AQP7, AQP9, or AQP10), proposed as aquaglyceroporins, can
transport water and small neutral solutes such as glycerol. AQPs now
appear to also play roles in tumor-associated edema, tumor cell prolifer-
ation andmigration, and tumor angiogenesis in solid and hematological
tumors. Marios C. Papadopoulos and Samira Saadoun [7] discuss the
key functions of aquaporins in tumor cells and how elucidating these
functions have allowed identifying novel therapeutic targets in cancer
biology.
Besides its pivot role in cellular metabolism as ubiquitous enzyme
cofactor and key source of cellular energy, ATP also functions as a potent
extracellular messenger via the activation of purinergic P2 receptors.
The latter comprise two subfamilies, the P2X ligand-gated ionotropic
channel family and the P2Y metabotropic, heptahelical G-protein
coupled receptor family. The P2X7 receptor, a member of the ﬁrst sub-
family, can function as a cation-selective ion channel or as nonselective
plasma membrane pore, and is heavily implicated in inﬂammation,
immune-modulation and tumor growth. S. Roger, B. Jelassi, I. Couillin,
P. Pelegrin, P. Besson and L. Jiang [8] present the current knowledge
andhypotheses on the involvement of the P2X7 receptors in the develop-
ment and progression of solid tumors, and highlight the aspects requiring
further clariﬁcation to decipher whether P2X7 might represent a cancer
biomarker or a pharmacological target.
Lipid rafts are speciﬁc membrane microdomains within the plasma
membrane lipid bilayer enriched in cholesterol, sphingolipids and gan-
gliosides. They usually function as triggers to bring different signaling
molecules into proximity with their substrates and to potentiate the
downstream intracellular signaling. Lipid rafts have been implicated in
the regulation of cell proliferation, differentiation, apoptosis andmigra-
tion, suggesting that alterations in these domains could be involved in
malignant transformation, invasiveness and metastasis. M. Guéguinou,
A. Gambade, R. Félix, A. Chantôme, Y. Fourbon, P. Bougnoux, G. Weber,
M. Potier-Cartereau and C. Vandier [9] focus on the lipid raft KCa/ClCa/
Ca2+ channel complexes that regulate Ca2+ signaling and Epithelial
Growth Factor Receptor signaling in cancer cells.
2. Cancers and alterations in the activities of membrane channels
The term “epigenetics” refers to modiﬁcations in gene expression
caused by heritable but potentially reversible changes in DNA and
chromatin structure. E pigenetic changes, particularly methylation
(the addition of a methyl group to carbon 5 of the cytosine within the
dinucleotide CpG) in gene promoters, are found in almost every type
of human neoplasm and are associatedwith transcriptional gene silenc-
ing. Aberrantmethylation is indeed correlatedwith the abnormalities in
expression of genes that are known to be involved in the particular
characteristics of cancer cells. H. Ouadid-Ahidouch, L. Rodat-Despoix,
F. Matifat, G. Morin, and A. Ahidouch [10] summarize the available
data on gene promoter methylation of ion channels. Dysregulation of
ion channel expression is indeed involved in tumorigenesis and cancer
cell properties such as proliferation, cell survival and invasiveness or re-
sistance to therapies.
All cells possess long-term, steady-state voltage gradients across the
plasma membrane, known as transmembrane potentials, arising from
the combined activity of numerous ion transporters, pumps and chan-
nels. This potential is known to drive a wide range of cellular processes
such as cellular proliferation, migration and tissue regeneration while
its deregulation can lead to tumorigenesis. Paul G. Barghouth, Manish
Thiruvalluvan and Néstor J. Oviedo [11] look into the biophysical ma-
chinery involving membrane potential and the mechanisms mediating
cell cycle progression and cancer transformation. They present the pla-
narian Schmidtea mediterranea as a tractable model system for under-
standing principles behind molecular bioelectricity at both the cellular
and organismal levels.
A hallmark of high-grade cancers is the ability of malignant cells to
invade unaffected tissue and spread disease via awell-deﬁned sequenceof events termed the metastatic cascade. This sequence includes the
disruption of the basementmembrane, the local invasion of the affected
tissue, followed by the intra- and extravasation of blood or lymph
vessels to ﬁnally develop a full-grown secondary tumor. The ability to
move is critical for the ability of tumor cells tometastasize. Ion channels
and transporters contribute to cell motility via an elaborate interplay
with components of the cytoskeleton, adhesion molecules, and signal-
ing cascades. Christian Stock and Albrecht Schwab [12] explain how
ion channels and transporters as well as aquaporins cooperate in
order to generate local pH or Ca2+ nanodomains required for cell adhe-
sion and cytoskeletal dynamics.
The growth, invasiveness andmetastatic potential of solid tumors re-
quire the formation of newblood vessels to providemetabolic support, to
overcome the basic surface/volume constraint in biological processes
and to sustain metastatic dissemination. Tumor neovascularization is
achieved by vasculogenesis fromendothelial precursors and by sprouting
angiogenesis from pre-existing vessels. The complex sequence of events
driving these processes is associated with ﬂuxes of ions, water and
other smallmoleculesmediated by a great pool of ion channels and trans-
porters (collectively designated as ‘transportome’). Luca Munaron [13]
provides an overview of the current literature on the involvement of
ion channels and transporters in the tumor angiogenic process, with a
particular focus on endothelial transportome diversity.
Apoptosis or genetically controlled cell death eliminates cells that
are no longer needed or are potentially harmful. Acquired resistance
to apoptosis represents the common feature of most and perhaps all
types of cancer. Ion channels, including Cl-, K+, Na+ and Ca2+ channels
as well as store-operated calcium channels, and transient receptor po-
tential (TRP) channels contribute to apoptotic cell shrinkage andmodify
intracellular ion composition. However, the contribution of speciﬁc ion
channels to apoptosis varies greatly depending on cell type, membrane
channel type and intracellular localization, pathology aswell as intracel-
lular signaling pathways involved. A. Kondratskyi, K. Kondratska, R.
Skryma and N. Prevarskaya [14] discuss the involvement of the major
types of ion channels in apoptosis regulatory pathways and the possible
use of these channels in cancer treatment.
Ionizing radiation represents a ‘two-edged sword’ in that it may lead
to genetic modiﬁcations in exposed, surviving normal tissue but may
also lead to loss of clonogenic survival of tumor cells, the latter deliver-
ing beneﬁt after radiotherapy. Discrete energy depositions during
passage of the ionizing radiation causes chemical modiﬁcations to the
biomolecules, particularly double strand breaks of DNA through forma-
tion of intermediate radicals. They also trigger a plethora of stress
responses, notably through the modulation of ion channels. Survival of
the tumor cells depends on both their capacity of oxidative defense
and their efﬁciency of DNA repair. S.M. Huber, L. Butz, B. Stegen, L.
Klumpp, D. Klumpp and F. Eckert [15] explain how radiogenic activation
of channels may contribute to radiogenic cell death as well as to DNA
repair, glucose fueling, radiogenic hypermigration or lowering of the
oxidative stress burden.
Paraneoplastic neurological or neuromuscular syndromes are
remote consequences of the presence of cancer in the body but are
not due to the local presence of the tumor or of its metastases. They
are indeed mediated by humoral factors excreted by tumor cells or by
an immune response against the tumor. Several autoantibodies directed
against ligand- or voltage-gated ion channels have already been identi-
ﬁed. Bastien Joubert and Jérôme Honnorat [16] focus on autoimmune
channelopathies in paraneoplastic neurological syndromes, ascribed to
autoimmune reactions against neuronal antigens ectopically expressed
by the underlying tumor or by cross-reaction with an unknown infec-
tious agent. Interestingly, these autoantibodies may represent speciﬁc
tools to investigate the functions of ion channels.
Bone pain is one of the most common complications in cancer
patients with bone metastases. Bone is maintained by the balance
of bone formation by osteoblasts and bone resorption mediated by
osteoclasts. Multinucleated giant osteoclasts continuously secrete
2475Editorialprotons to maintain bone homeostasis in physiological conditions but
this secretion is enhanced in response to the bone modifying factors
produced by bone-colonizing cancer cells. The resulting acidic extracel-
lular microenvironment not only activates certain channels (e.g. acid-
sensing ion channels and TRPV channels), but also sensitizes primary af-
ferent nociceptors, thereby contributing to metastatic cancer pain. T.
Yoneda, M. Hiasa, Y. Nagata, T. Okui and F. White [17] examine these
mechanisms and the potential therapeutic implications of blocking the
development and recognition of acidic microenvironment.
3. Membrane channels in cancer management strategies
Carcinogenesis is amulti-step process that requires a series of essen-
tial genetic aberrations in order to give rise to an invasive tumor. In the-
ory, this lengthy development would provide sufﬁcient time to detect
the tumor and counteract the tumorigenesis process. In fact, in most
cases, tumors develop without symptoms and thus remain undetected
until the ﬁnal phases. One way to improve clinical management of
cancer lies in identiﬁcation of biomarkers that can be applied for early
detection, diagnosis, prognosis, treatment response prediction or treat-
ment monitoring. Elena Lastraioli, Jessica Iorio and Annarosa Arcangeli
[18] explain how ion channels and transporters, which control many
“cancer hallmarks” in different types of human cancers, are progressive-
ly emerging as novel cancer biomarkers, behaving either as diagnostic,
prognostic or predictive markers.
Sigma receptors, originally described as a type of opiate receptor,
were later recognized as a distinct pharmacological entity distinguished
by its unusually promiscuous ability to bind a wide variety of drugs. Al-
though sigma receptors are over-expressed in tumors and up-regulated
in rapidly dividing normal tissues, their ligands induce signiﬁcant
cell death only in tumor tissue. Sigma ligands may therefore be used
to selectively eradicate tumors. A. van Waarde, A.A. Rybczynska, N.K.
Ramakrishnan, K. Ishiwata, P.H. Elsinga and R.A. Dierckx [19] explain
that multiple mechanisms appear to underlie the inhibition of tumor
growth and cell death triggered by sigma ligands, and that the signaling
pathways depend on both the type of ligand and the type of tumor cell,
resulting in somewhat conﬂicting reports in the oncological literature.
Most cancer cells shift theirmetabolic pathway fromoxidative phos-
phorylation to aerobic glycolysis, producing lactate from glucose, to en-
sure the high level of ATP necessary for their proliferation. This shift
creates an acidic microenvironment around the tumor which encour-
ages a selection of certain cell phenotypes that are able to survive in
this caustic environment to the detriment of other cell types. Moreover,
a vast majority of anticancer drugs do not enter into cancer cells when
protonated into the acidic tumor microenvironment. E.P. Spugnini, P.
Sonveaux, C. Stock, M. Perez-Sayans, A. De Milito, S. Avnet, A.G. Garcìa,
S. Harguindey and S. Fais [20] critically present the background of a
novel and efﬁcient approach that aims to ﬁght cancer through blocking
or inhibiting well characterized proton exchangers and transporters ac-
tive in human cancer cells.
Antitumor therapies may expose patients to cardiovascular discom-
forts such as transient blood pressure instability, supraventricular
arrhythmias or sporadic benign ventricular arrhythmias. In most cases,
suchdisorders occur acutely, revert spontaneously or respond to cardio-
vascular therapies, and do not form an indication to interrupting
therapy. In some cases however, cancer treatment is associated with
life-threatening arrhythmia, ischaemia, infarction, and damage to cardi-
ac valves, the conduction system or the pericardium. E. Salvatorelli,
P. Menna, E. Cantalupo, M. Chello, E. Covino, F.I. Wolf and G. Minotti
[21] examine the literature concerning the cardiovascular complications
of cancer treatments to point out that collaboration between cardiolo-
gists and oncologists is essential to the concomitant management of
cancer therapy and cardiac therapy.
Chemotherapy-induced nausea and vomiting (CINV) is associat-
ed with a signiﬁcant deterioration in quality of life of patients receiv-
ing some anti-neoplastic therapies. CINV can indeed result in seriousconsequences such as weakness, weight loss, electrolyte imbalance,
dehydration, or anorexia, with possible complications as fractures,
oesophageal tears, decline in behavioral and mental status, and
wound dehiscence. Rudolph M. Navari [22] describes the mechanisms
of the sensation of nausea and the act of vomiting (protective reﬂexes
to rid the stomach and intestine of toxic substances) and provides an
overview of the current antiemetic treatments developed to alleviate
the ﬁve categories of CINV occurring at different times of the adminis-
tration of chemotherapy (anticipatory, acute, delayed, breakthrough
and refractory).
Although discovery and development of novel and effective anti-
cancer drugs is a major research area, oncology drug development
remains a lengthy process, extremely costly and with high attrition
rates. Therefore, a strong interest has emerged to identify approved
non-cancer drugs that also possess anti-cancer activity, thus shortcut-
ting the development process. This research strategy, known as drug
repurposing or drug repositioning, provides a faster path to the clinics.
As the repositioned drug has already passed a signiﬁcant series of toxic-
ity and other tests as well as clinical trial before being introduced in the
market, several toxicity issues will be omitted for further use in other
purposes. Vijay Pralhad Kale, Shantu G. Amin and Manoj K. Pandey
[23] discuss the possibility of repurposing approved drugs, particularly
ion channel inhibitors (e.g. K+ or Ca2+ channel blockers), as cancer
therapeutics.
The growing demand for communication devices resulted in an
enormous increase in environmental exposure to electromagnetic radi-
ations and radiofrequency ﬁelds, whichmay affect biological systems by
increasing free radicals, which appearmainly to enhance lipid peroxida-
tion, and by changing the antioxidant defense systems of human tissues,
thus leading to oxidative stress. Bilal Çiğ and Mustafa Nazıroğlu [24]
report that Wi-Fi andmobile phone placed within 10 cm of the cells in-
duced excessive oxidative responses and apoptosis via TRPV1-induced
cytosolic Ca2+ accumulation in the cancer cells.
I wish to thank all authors and co-authors for their commitment and
the anonymous reviewerswho contributed by their critical constructive
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